Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely
Vicarious Surgical Is Maintained at Neutral by Piper Sandler
Vicarious Surgical Analyst Ratings
TD Cowen Maintains Vicarious Surgical(RBOT.US) With Buy Rating, Raises Target Price to $13
Promising Milestones and Financial Prudence Drive Buy Rating for Vicarious Surgical
BTIG Maintains Vicarious Surgical(RBOT.US) With Hold Rating
Vicarious Surgical (RBOT) Gets a Hold From BTIG
Express News | Vicarious Surgical Inc : Piper Sandler Cuts Target Price to $10.50 From $12
Vicarious Surgical Inc. (RBOT) Q3 2024 Earnings Call Transcript Summary
Vicarious Surgical | 10-Q: Q3 2024 Earnings Report
Vicarious Surgical | 8-K: Vicarious Surgical Reports Third Quarter 2024 Financial Results
Vicarious Surgical Reports Q3 Adjusted EPS ($2.87), Consensus ($2.55)
Vicarious Surgical Backs FY24 Cash Burn View Roughly $50M
Earnings Flash (RBOT) VICARIOUS SURGICAL Posts Q3 Loss $-2.87
Vicarious Surgical Reports Third Quarter 2024 Financial Results
NYSE Net Change Percentage Gainers & Losers
Earnings Preview: RBOT to Report Financial Results Post-market on November 12
Vicarious Surgical to Report Third Quarter 2024 Financial Results on November 12, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Session
Vicarious Surgical Inc (RBOT) Q2 2024 Earnings Call Highlights: Strategic Partnerships and ...
No Data
No Data